Uracil or thymine derivative for treating hepatitis C

• Main Authors: HENRY, RODGER F, HUANG, PEGGY P, LONGENECKER, KENTON L, HAIGHT, ANTHONY R, LIU, DACHUN, DONNER, PAMELA L, RANDOLPH, JOHN T, FRANCZYK II, THADDEUS S, ROCKWAY, TODD W, GAO, YI, TUFANO, MICHAEL D, KATI, WARREN M, HUTCHINSON, DOUGLAS K, FLENTGE, CHARLES A, KRUEGER, ALLAN C, BETEBENNER, DAVID A, SARRIS, KATHY, MARING, CLARENCE J, DEGOEY, DAVID A, WAGNER, ROLF, LOU, XIAOCHUN, ZHANG, GEOFF G. Z, CHEN, SHUANG, PRATT, JOHN K, STEWART, KENT D, HENGEVELD, JOHN E, BARNES, DAVID M, KOTECKI, BRIAN J, MOTTER, CHRISTOPHER E, LIU, YAYA
• Format: Patent
• Language: English
• Published: 06.11.2014
• Subjects: CHEMISTRY; HETEROCYCLIC COMPOUNDS; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

Present application relates to the compounds of formula I useful to treat hepatitis C (HCV) infections. In the structure of the disclosed compounds is the uracil or thymine derivative linked via a phenylene into either fused 2-ring cyclic system (R6) or alternatively via additional two-atom linker (L) to a 5-6 membered monocycle (R6). Application further discloses polymorphs and pseudopolymorphs of two specific compounds: N-(6(3-t-butyl-5-(2>4-dioxo-3,4-dihydropyrimidin-1 (2H)- y!)2-methoxy-phenyl)naphthalen-2-yl)methanesulfonamide and (E)-N-(4(3-t- butyl-5-(2,4-dioxo-3)4-dihydropyrimidin-1 (2H)-yl)2-methoxy-styryl- phenyl)methanesulfonamide.